Today, we have just finalized the entry of three shareholders into the company MIMO. MIMO is a start-up from the CIMA that provides services to various pharmaceutical companies to accelerate efficacy studies for their drugs, to reach patients sooner. It focuses on hematological diseases such as multiple myeloma and lymphoma.
Special thanks to Sanitas, 3-GUTINVER SL, and David Zubeldia for making this project possible. My admiration and gratitude go to MIMO's management team, especially its CEO, Ricardo Perez Merino, and its CSO, José Ángel Martínez Climent.
This project would not have been possible without the hidden efforts of CREA Inversion, our lawyer Gerardo Zalba, and the incredible team I lead: Antonio Pineda-Lucena, PhD, Lucia Vanrell, Rubén Pío, Jorge Ramos, and Maria Mora Catalá. María has handled a significant part of this project with great professionalism.
It is an honor for me to share their research vision and dedication. Congratulations to everyone!